Novasep unveils new divisional structure

Groupe Novasep has provided an update on the structural changes at
the company in the wake of its merger with Dynamic Synthesis in
January.

The group will operate on the market as two distinct networks, called Novasep Synthesis and Novasep Process. The former will provide R&D services and custom synthesis, from the laboratory to industrial scale, with the combined expertise of the following business lines: Dynamit Nobel (specialized in hazardous chemistry), Rohner (transition metal catalysis), Finorga (experts in chiral chemistry) and Séripharm (specialized in high potency products).

Meanwhile, Novasep Process will offer research and purification solutions based on chromatography, ion exchange, membranes, crystallization and downstream bioprocesses, and its network will include Novasep SAS (chromatography and crystallisation solutions for pharmaceutical companies), Applexion (chromatography, ion exchange for the foods and biotech markets) and Orelis (specialising in cross-flow filtration).

Roger Marc-Nicoud, Groupe Novasep's president and founder, said the new structure would 'maximize synergies between the resources of the group, give customers access to all the resources of the group via a single local contact, and keep the local management empowered to ensure an entrepreneurial and reactive behaviour'.

"In the life science market today, customers demand higher purity levels, cost-efficient solutions, strict regulatory and operational controls and shorter times to market,"​ he said.

A new logo (pictured) has been designed to represent all the business lines and activities of the group.

Related news

Show more

Related products

show more

Solution for challenging antibodies – Planova™ S20N

Solution for challenging antibodies – Planova™ S20N

Content provided by Asahi Kasei Medical Co., Ltd. | 24-Sep-2024 | White Paper

Designed as a next generation cellulose-based virus removal filter, Planova™ S20N has demonstrated robust filtration performance for challenging molecules...

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Follow us

Products

View more

Webinars